Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy

Technology appraisal guidance
Reference number: TA378
Published: 27 January 2016

Download (PDF)

What has NICE said?

Ramucirumab (Cyramza) is not recommended for advanced gastric cancer or gastro–oesophageal junction adenocarcinoma that has already been treated with chemotherapy.

What does this mean for me?

If you are already taking ramucirumab for advanced gastric cancer or gastro–oesophageal junction adenocarcinoma, you should be able to continue taking it until you and your doctor decide it is the right time to stop.